Keystone Financial Group (Georgia)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$263K Sell
1,045
-94
-8% -$20.2K 0.14% 49
2026
Q1
$248K Buy
1,139
+3
+0.3% +$665 0.13% 52
2025
Q4
$260K Buy
1,136
+2
+0.2% +$456 0.14% 52
2025
Q3
$262K Buy
1,134
+4
+0.4% +$815 0.15% 54
2025
Q2
$216K Buy
1,130
+3
+0.3% +$558 0.14% 56
2025
Q1
$213K Sell
1,127
-36
-3% -$7K 0.15% 55
2024
Q4
$207K Buy
+1,163
New +$214K 0.17% 66

Other funds holding ABBV

Keystone Financial Group (Georgia)'s ABBV Position: Q2 2026 in Review

Keystone Financial Group (Georgia) reduced its AbbVie (ABBV) stake by 8.3% in Q2 2026, selling an estimated $20.2K and leaving 1,045 shares worth $263K. The position accounts for 0.14% of the portfolio, ranked #49.

Keystone Financial Group (Georgia) first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Keystone Financial Group (Georgia) held 1,045 shares of AbbVie worth $263K as of Q2 2026.
  • Keystone Financial Group (Georgia) sold 94 AbbVie shares in Q2 2026, an estimated $20.2K.
  • AbbVie made up 0.14% of Keystone Financial Group (Georgia)'s portfolio in Q2 2026, its #49 holding.
  • Keystone Financial Group (Georgia) first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Keystone Financial Group (Georgia)'s 13F filing for Q2 2026, filed 21 Jul 2026.